Dry eyes come with discomfort and pain. It can be irritating, and statistics show that more than 15 million detected cases of dry eye syndrome in the United States. Meanwhile, it is emerging that there is no permanent cure for dry eye disease currently. However, the market is poised to welcome a potential candidate from Aldeyra Therapeutics Inc. (NASDAQ:ALDX), reproxalap.
The clinical-stage biotechnology company is passionate about improving the lives of patients with immune-mediated diseases. As a result, it will put in a New Drug Application (NDA) for reproxalap commonly referred to as reactive aldehyde species (RASP) inhibitor.
There Is Already an Objective Sign of Positive Progress in the Regulatory Of Novel Treatments
There are increased cases of dry eyes, and performing everyday functions such as driving or reading is becoming a nightmare for hundreds of people. Unfortunately, the lack of novel treatments has forced people to turn to nutritional supplements, punctal plugs, and topical medication.
Nonetheless, despite all this, Aldeyra Therapeutics believes that there is still an open window to arrest this chronic disorder through the development of novel solutions. Though still an investigation candidate, Reproxalap is already showing positive progress as a novel treatment.
Meeting minutes between Aldeyra and the U.S. Food and Drug Administration (FDA) have outlined positive progress for the treatment. It will likely open doors of regulation for the development of other treatments. Whether or not results from the first of the RASP trials will be out by the end of 2020 will be determined by the direction the by the end of 2020.
Aldeyra Is Using Selective Technology to Develop Novel Nano-Particle Based Therapeutic Solutions
“With only one drug approved in the United States for… dry eye disease, the need for therapeutic options with new mechanisms of action is substantial.” President and CEO of Aldeyra, Todd C. Brady reported.
The company has vowed to overlook any potential obstacle to improve the efficiency of drug delivery. That means deploying the use of advanced technology, including mucus-penetrating particles, to develop therapeutic solutions for eye diseases. The company is already enjoying a strong intellectual property portfolio.